Benign Prostatic Hyperplasia (BPH) Devices Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, France, China, Ireland, Canada - Size and Forecast 2024-2028

Benign Prostatic Hyperplasia Devices Market Size 2024-2028

The benign prostatic hyperplasia (BPH) devices market size is forecast to increase by USD 2.93 billion at a CAGR of 4.5% between 2023 and 2028.

• The market is experiencing significant growth due to several key factors. The increasing prevalence of BPH, driven by aging populations and associated risk factors, is a major market driver. Additionally, the preference for minimally invasive, in-office surgical techniques is on the rise, providing opportunities for market expansion. However, the high cost of BPH treatment remains a major challenge for the market, limiting the accessibility of healthcare services to a large patient population. Despite this, the market is expected to continue its growth trajectory, driven by medical technological advancements and the development of cost-effective treatment options.

What will be the Size of the Benign Prostatic Hyperplasia (BPH) Devices Market During the Forecast Period?

Request Free Sample

• The market is experiencing significant growth due to the increasing awareness and diagnosis of urological disorders among the elderly population. This market is driven by the demand for minimally invasive treatments, including laser therapies such as Aquablation and robot-assisted surgeries, which offer faster recovery times and improved quality of life for patients. Urological disorders, such as Benign Prostatic Hyperplasia (BPH), often necessitate medical robotics intervention for effective management. Innovative treatments, such as the Urolift System and Prostatic Urethral Lift, are also gaining popularity due to their minimal invasiveness and effectiveness in relieving symptoms.

• Technological advancements in urology lasers, electrosurgical generators, and transurethral needle ablation are further fueling market growth. However, concerns regarding potential kidney damage and the high cost of these procedures may limit market expansion. The healthcare sector continues to invest in hospital treatments and outpatient surgeries to meet the increasing demand for BPH treatments, making this market a key area of focus for industry players.

How is this Benign Prostatic Hyperplasia (BPH) Devices Industry segmented and which is the largest segment?

The benign prostatic hyperplasia devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Therapy
  • TURP
  • Laser therapy
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • France
  • Asia
    • China
  • Rest of World (ROW)

By Therapy Insights

• The TURP segment is estimated to witness significant growth during the forecast period.

Benign Prostatic Hyperplasia (BPH) is a common condition among older men, leading to urinary symptoms. Transurethral resection of the prostate (TURP) has long been the standard treatment for BPH, with approximately 150,000 procedures performed annually In the US. However, the need for hospital stays, lengthy recovery time, and highly skilled surgeons restrict the growth of this segment. Moreover, Minimally Invasive Surgical Therapies (MISTs), such as laser therapies, have emerged as potential alternatives to TURP, hindering its growth. In the healthcare sector, innovative treatments, including robot-assisted surgery and electrosurgical generators, are gaining popularity. Product recalls and hospital treatments add to the complexity of the BPH devices market.

Furthermore, urology lasers play a significant role In the treatment of BPH, offering less invasive options with faster recovery times. Despite challenges, the BPH devices market continues to grow, driven by the increasing prevalence of BPH and the development of advanced technologies.

Get a glance at the Benign Prostatic Hyperplasia (BPH) Devices Industry report of share of various segments Request Free Sample

The TURP segment was valued at USD 4.31 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 47% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America experienced significant growth in 2023, with the US, Canada, and Mexico being the primary contributors. The aging population is the major driving factor for the market's expansion. With the increasing number of baby boomers, lifestyle changes, and unhealthy diets have led to an increase in health issues, including urinary incontinence. Obesity is another contributing factor to the development of BPH due to changes in endocrine conditions, increased sympathetic nerve activity, elevated inflammatory responses, and oxidative stress.

Technological advancements have led to the development of minimally invasive surgeries and homeopathic treatments, providing effective solutions for BPH patients. The BPH devices market in North America is expected to continue its growth trajectory due to the increasing prevalence of BPH and the availability of innovative treatment options.

Market Dynamics

Our benign prostatic hyperplasia (BPH) devices market researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Benign Prostatic Hyperplasia (BPH) Devices Industry?

The increasing prevalence of BPH coupled with increasing risk factors is the key driver of the market.

• Benign Prostatic Hyperplasia (BPH), a common urological disorder in aging men, affects approximately 10% of men In their 30s, 20% In their 40s, and up to 90% In their 70s and 80s. The elderly population, which is growing rapidly due to increased life expectancy, is particularly susceptible to this condition. BPH treatment devices have gained significant attention In the healthcare sector due to the need for minimally invasive technologies that improve patient outcomes and reduce recovery times. Laser treatments, such as Elesta Echo-Laser and various Urology lasers, have emerged as popular options for BPH treatment. Minimally invasive surgeries, including robot-assisted surgery, transurethral needle ablation, prostatic urethral lift, prostate artery embolization, and optilume drug-coated balloon, are increasingly being adopted for their effectiveness and minimal side effects.
• Innovative treatments, like aquablation and ablation treatment procedures, are also gaining traction In the market. The iTind device, transurethral microwave therapy, and prostatic stenting are other minimally invasive treatment options that offer improved quality of life for patients. Hospitals and clinics offer various treatment options, including homeopathy, alpha-blockers, and urinary tract infection treatment, depending on the severity of the condition. The prostate treatment market is expected to grow due to the increasing prevalence of BPH and the availability of reimbursement facilities and healthcare expenditures. Technological advancements, such as minimally invasive surgeries and innovative treatments, are driving the growth of the market.

What are the market trends shaping the Benign Prostatic Hyperplasia (BPH) Devices Industry?

Increasing preference for in-office-based minimally invasive surgical techniques is the upcoming market trend.

• Benign Prostatic Hyperplasia (BPH), a common urological disorder among the elderly population, necessitates treatment to alleviate symptoms such as urinary frequency, urgency, and incomplete bladder emptying. Traditional treatment methods, including transurethral resection of the prostate (TURP), have been associated with prolonged recovery times and hospital stays. However, technological advancements have led to the emergence of minimally invasive BPH treatment devices. Minimally invasive treatments, including laser ablation (Aquablation, Elesta Echo-Laser Treatment), transurethral needle ablation (TUNA), prostatic urethral lift, and prostate artery embolization, have gained popularity due to their safety, efficacy, and durability. These procedures can be performed in a physician's office or outpatient setting, reducing the need for hospitalization.

• Minimally invasive surgeries, such as laser surgery and transurethral microwave therapy, offer quicker recovery times and improved quality of life. Prostatic stenting and the iTind device are other minimally invasive treatment options that have shown promise in managing BPH symptoms. The healthcare sector's increasing focus on innovative treatments and reimbursement facilities has accelerated the product launch of these minimally invasive BPH treatment devices. However, product recalls due to complications, such as urinary tract infections and kidney damage, have raised concerns regarding their safety. Urologists and healthcare providers continue to evaluate the long-term efficacy and safety of these minimally invasive treatments compared to traditional surgical procedures.

What challenges does the Benign Prostatic Hyperplasia (BPH) Devices Industry face during its growth?

The high cost of BPH treatment is a key challenge affecting the industry growth.

• Benign Prostatic Hyperplasia (BPH) is a common urological disorder affecting the elderly population, leading to urinary symptoms and decreased quality of life. Treatment devices for BPH include minimally invasive technologies such as laser treatments, transurethral needle ablation, prostatic urethral lift, prostate artery embolization, and optilume drug-coated balloon. These innovative treatments offer shorter recovery times and improved patient outcomes compared to traditional hospital treatments like prostatectomy and transurethral microwave therapy. The increasing awareness of BPH and its impact on patient quality of life has led to a growing demand for cost-effective treatment options.

• The cost of treatment varies significantly depending on the procedure, surgeon fees, anesthesia costs, and hospital or surgical center charges. The healthcare sector is witnessing technological advancements In the form of minimally invasive surgeries, such as elesta echo-laser treatment, ablation treatment procedures, iTind device, and prostatic stenting. These procedures offer several advantages, including reduced hospital stays, shorter recovery times, and lower risks of complications like urinary tract infections and kidney damage. Reimbursement facilities and healthcare expenditures also play a crucial role In the selection of treatment options for patients. Product launches and continuous innovation In the BPH treatment market are expected to further drive market growth.

Exclusive Customer Landscape

The benign prostatic hyperplasia (BPH) devices market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the benign prostatic hyperplasia (BPH) devices market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, benign prostatic hyperplasia (BPH) devices market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Astellas Pharma Inc.
• biolitec AG
• Boston Scientific Corp.
• Butterfly Medical
• Coloplast AS
• Convergent Laser Technologies
• IPG Photonics Corp.
• KARL STORZ SE and Co. KG
• Medeon Biodesign Inc.
• Medifocus Inc.
• Olympus Europa SE and Co. KG
• OmniGuide Holdings Inc.
• ProArc Medical
• Richard Wolf GmbH
• SRS Medical
• Teleflex Inc.
• Urologix LLC
• Vendor Credentialing Service LLC
• Zenflow Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Benign Prostatic Hyperplasia (BPH) is a common urological disorder affecting older men, characterized by the enlargement of the prostate gland. This condition leads to various symptoms such as frequent urination, difficulty in initiating urination, and a weak urine stream. The healthcare sector has witnessed significant advancements in the development of treatment devices aimed at addressing BPH and improving the quality of life for affected individuals, with innovations in blood diagnostics and photonics playing a key role in enhancing these treatments. Patient awareness and education play a crucial role In the adoption of these innovative treatments. As the elderly population continues to grow, so does the prevalence of BPH. The healthcare sector is responding to this trend by investing in minimally invasive technologies, which offer several advantages over traditional hospital treatments.

Moreover, Laser treatments have emerged as a popular choice for BPH patients. These procedures utilize focused beams of light to remove or vaporize prostate tissue, providing effective relief from symptoms. Minimally invasive surgeries, such as aquablation and transurethral needle ablation, offer faster recovery times and reduced risk of complications compared to open prostatectomy. Robot-assisted surgery is another minimally invasive technology gaining traction in the BPH treatment market. This advanced procedure allows for precise and accurate removal of prostate tissue, resulting in improved outcomes and reduced hospital stays. Electrosurgical generators are essential tools used in various urological procedures, including BPH treatments, to generate electrical energy for cutting and coagulation.

Furthermore, the prostate treatment market is witnessing a rise in product launches, driven by technological advancements and growing demand for minimally invasive treatments. Urology lasers, such as elesta echo-laser treatment, offer targeted and effective solutions for BPH. Prostatic urethral lift, prostate artery embolization, and optilume drug-coated balloon are other innovative treatments that have gained popularity due to their minimally invasive nature and quick recovery times. The healthcare sector's investment In these advanced treatments is driven by the growing geriatric population and the need to address the rising prevalence of BPH. Reimbursement facilities and healthcare expenditure are also key factors influencing the growth of the BPH treatment market.

Request Free Sample

What are the Key Data Covered in this Benign Prostatic Hyperplasia (BPH) Devices Market Research and Growth Report?

• CAGR of the Benign Prostatic Hyperplasia (BPH) Devices industry during the forecast period
• Detailed information on factors that will drive the Benign Prostatic Hyperplasia (BPH) Devices market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the benign prostatic hyperplasia (BPH) devices market growth of industry companies

We can help! Our analysts can customize this benign prostatic hyperplasia (BPH) devices market research report to meet your requirements.

Get in touch